HCV and HBV infection among multitransfused thalassemics from eastern Sicily.
Serum specimens from 152 Sicilian multitransfused thalassemic subjects were tested for antibodies to hepatitis C virus (anti- HCV) and for HBV markers by enzyme linked immunoassay and with reference to anti-HCV, confirmed by recombinant immunoblot assay. A high rate (47%) of subjects was anti-HCV positive. HBsAg was found in 8% of patients and 55% had anti-HBs or anti-HBc antibodies or both. Contrary to HBV infection, anti-HCV seropositivity was related to the number of transfused units. The highest anti-HCV prevalence was observed between 16 and 20 years; 100% of persons older than 50 years had at least one marker of HBV infection. In conclusion, HCV and HBV are widespread among multitransfused thalassemic. Probably in our area, particularly during the pre-HBsAg screening era, several multitransfused patients were infected by HBV more readily than by HCV.
Cacopardo
B
B
Institute of Infectious Diseases, University of Catania, Italy.
Russo
R
R
Fatuzzo
F
F
Cosentino
S
S
Lombardo
T
T
La Rosa
R
R
Celesia
B M
BM
Nigro
L
L
Frontini
V
V
Nunnari
A
A
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology*; D006510:Hepatitis B Antibodies / Q000097:blood; D006526:Hepatitis C / Q000150:complications / Q000453:epidemiology*; D018937:Hepatitis C Antibodies; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D012802:Sicily / Q000453:epidemiology; D013789:Thalassemia / Q000150:complications* / Q000628:therapy
D006508:Hepatitis Antibodies; D006510:Hepatitis B Antibodies; D018937:Hepatitis C Antibodies